LOS ANGELES--(BUSINESS WIRE)--The OrthoSonos Health Index (OHI) reports data captured through an innovative medical device, OrthoSonos, during a sit and stand procedure to determine the health of joints and prosthetic implants. OrthoSonos is being revealed to a select group of physicians at an invite-only event during the American Academy of Orthopedic Surgeons (AAOS) Annual Meeting in New Orleans on March 13th.
“Traditional tools for evaluating joint health take a static view of the joint, but the real innovation here is that OrthoSonos gathers signals of friction and degradation from moving joints across a range of motion that is much more realistic of use,” said Martin Burns, CEO of Bruin Biometrics.
Interim results from a clinical study show OHI values from patients with knee implants increasing in the first three years – a suspected “bedding in” stage – followed by a steady decline to near zero after approximately 10 years of use. High positive values are indicative of joints that are gliding smoothly with minimal audible friction. Low values are indicative of friction and degradation.
“The promise of OrthoSonos is to provide orthopedic surgeons and rheumatologists with dynamic joint health assessment data gathered in-office, in real time and without side effects to patients,” Burns said.
Physicians wanting to learn more about OrthoSonos and the reveal event on March 13th should contact Dr. Herman Lelie (firstname.lastname@example.org) or Anasheh Shamirian (email@example.com).
About Bruin Biometrics
Bruin Biometrics (BBI) is relentlessly committed to using technology to improve the way that health care is delivered. By developing innovative biometric medical device systems that can cost-effectively detect and monitor select medical conditions with urgent clinical needs, BBI is helping inform clinical decisions, simplify patient care and improve patient outcomes. BBI has developed the SEM Scanner, a revolutionary wound care medical device to detect the inflammatory changes associated with pressure induced tissue damage. BBI’s second product, the OrthoSonos, is an innovative medical device to diagnose and spot monitor the health of joints and prosthetic implants. Neither SEM Scanner nor OrthoSonos are approved for sale by the FDA. The SEM scanner has been CE Mark approved in the EU and is currently in full commercial launch. OrthoSonos is on track for commercial launch in Q4, 2014. To learn more about BBI, please visit www.bruinbiometrics.com.